These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17535539

  • 1. Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
    Straka RJ, Mamdani M, Damen J, Kuntze CE, Liu LZ, Botteman MF, Koren MJ.
    Curr Med Res Opin; 2007 Jul; 23(7):1517-29. PubMed ID: 17535539
    [Abstract] [Full Text] [Related]

  • 2. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
    Attanasio E, Russo P, Allen SE.
    Clin Ther; 2001 Feb; 23(2):276-83; discussion 274-5. PubMed ID: 11293560
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL, Lyseng-Williamson KA.
    Pharmacoeconomics; 2007 Feb; 25(12):1031-53. PubMed ID: 18047388
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The value of atorvastatin over the product life cycle in the United States.
    Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P.
    Am J Cardiovasc Drugs; 2006 Oct; 6(3):177-88. PubMed ID: 16780391
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ, Smith DG, Hunninghake DB, Davidson MH, McKenney JM, Weiss SR, Schrott HG, Henley RW, Tresh P, McLain RW, Bakker-Arkema RG, Black DM.
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS.
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [Abstract] [Full Text] [Related]

  • 20. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S, Sinnaeve PR.
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.